| Aug 9 |
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
|
| Aug 9 |
Xenon Pharma files for automatic mixed securities shelf
|
| Aug 9 |
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
|
| Aug 8 |
Xenon Pharmaceuticals: Q2 Earnings Snapshot
|
| Aug 8 |
Xenon Pharma GAAP EPS of -$0.75 misses by $0.04
|
| Aug 8 |
Xenon Reports Q2 2024 Financial Results and Business Update
|
| Aug 7 |
Xenon Pharma Q2 2024 Earnings Preview
|
| Aug 1 |
Xenon to Report Q2 2024 Financial Results on August 8, 2024
|
| Jul 16 |
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 24% Below Their Intrinsic Value Estimate
|
